<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03822455</url>
  </required_header>
  <id_info>
    <org_study_id>ORDCF205</org_study_id>
    <nct_id>NCT03822455</nct_id>
  </id_info>
  <brief_title>A Phase 2b Randomised, Placebo Controlled Study of OligoG in Patients With Cystic Fibrosis</brief_title>
  <official_title>A Phase 2b Randomised, Double-blind, Parallel-group Study of Alginate Oligosaccharide (OligoG) Dry Powder Inhalation in Addition to Standard of Care Compared to Placebo in Addition to Standard of Care in Patients With Cystic Fibrosis (CF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AlgiPharma AS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AlgiPharma Australia Pty. Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>AlgiPharma AS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A double-blind, randomised study of OligoG DPI compared to placebo DPI, both on top of&#xD;
      standard-of-care, to assess safety, efficacy and tolerability. Adult patients with Cystic&#xD;
      Fibrosis will be included in the study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The alginate oligosaccharide OligoG CF-5/20 dry powder for inhalation (OligoG DPI) represents&#xD;
      a novel therapeutic approach for patients with cystic fibrosis (CF). OligoG has been shown to&#xD;
      release stagnant mucus, modulate sputum rheology and disrupt the biofilm formation often&#xD;
      typically observed in CF. These properties will in turn facilitate mucus clearance and&#xD;
      promote effectiveness of antibiotic therapy against the chronic pulmonary infections&#xD;
      characteristic of CF.&#xD;
&#xD;
      Patients with CF (age 18 years or older) will be eligible to participate in this study.&#xD;
&#xD;
      The design will be a randomised, blinded, placebo-controlled pilot study for proof of concept&#xD;
      that OligoG DPI can improve lung function in adult CF patients. Study medication will be&#xD;
      given twice daily for twelve weeks on top of standard of care (SOC). Thirty-three patients&#xD;
      will be included, out of which twenty-two shall receive OligoG, and eleven shall receive&#xD;
      placebo.&#xD;
&#xD;
      After all patients have completed the 12 week double blind treatment period, all patients&#xD;
      will be offered open-label OligoG twice daily, in addition to standard of care, for 12&#xD;
      months.&#xD;
&#xD;
      The primary endpoint will be absolute change i percent predicted FEV1&#xD;
&#xD;
      Exploratory parameters will include sputum microbiology.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">May 16, 2019</start_date>
  <completion_date type="Anticipated">July 10, 2021</completion_date>
  <primary_completion_date type="Actual">March 11, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomised, double blind, placebo controlled</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Patients will be randomised to receive OligoG or placebo DPI. The investigational medicinal products will have identical appearance</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>FEV1 percent predicted</measure>
    <time_frame>Baseline compared to 12 weeks</time_frame>
    <description>Absolute change in percent Forced Expiratory Volume in one second,</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pulmonary exacerbation rate</measure>
    <time_frame>6 months before treatment, 6 months after treatment,</time_frame>
    <description>rate of pulmonary exacerbations</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>OligoG DPI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active DPI containing the oligosaccharide OligoG and excipients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo DPI</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo DPI containing lactose and excipients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OligoG DPI</intervention_name>
    <description>OligoG Dry Powder for Inhalation</description>
    <arm_group_label>OligoG DPI</arm_group_label>
    <arm_group_label>Placebo DPI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Genotypic confirmation of CFTR mutation or clinical diagnosis of Cystic Fibrosis (CF)&#xD;
             confirmed by a sweat chloride value ≥60 mmol/L by quantitative pilocarpine&#xD;
             iontophoresis.&#xD;
&#xD;
          -  Age 18 years or older.&#xD;
&#xD;
          -  Male or female patients with any ethnicity.&#xD;
&#xD;
          -  FEV1 at screening in the range of ≥40% and 90% of the predicted normal for age, sex,&#xD;
             and height, according to the GLI equation (Eur Respir J. Dec 2012; 40(6): 1324-1343).&#xD;
&#xD;
          -  History of Pseudomonas aeruginosa (PA) infection with at least one positive&#xD;
             microbiological PA testing during the last 12 months before the Screening Visit.&#xD;
&#xD;
          -  History of antibiotic treatment due to PA infection (not for eradication therapy)&#xD;
             during the last 12 months&#xD;
&#xD;
          -  Concomitant treatment with inhaled tobramycin, colistin, or aztreonam (either cycled&#xD;
             or continuous) for at least 3 months at screening to treat PA infection. In case of&#xD;
             cycled antibiotic treatment, the treatment should start with an active cycle at the&#xD;
             day of randomisation (+/- 2 day) (together with the IMP intake). If taking tobramycin&#xD;
             cycled with another antibiotic, IMP should start on the active cycle of tobramycin.&#xD;
&#xD;
          -  Stable CF disease as judged by the investigator.&#xD;
&#xD;
          -  Willing to remain on a stable CF medication regimen (standard of care; SOC) during the&#xD;
             study.&#xD;
&#xD;
          -  Women of child-bearing potential must have a negative urine pregnancy test at the&#xD;
             Screening and Randomisation Visit.&#xD;
&#xD;
          -  Male and female patients must use acceptable contraceptive methods for the duration of&#xD;
             the study. Male and female patients without child-bearing potential (i.e. who are&#xD;
             infertile, surgically sterile or post-menopausal) are exempted from the contraceptive&#xD;
             requirements. For the purpose of this study acceptable contraception is defined as one&#xD;
             or a combination of the following:&#xD;
&#xD;
               -  oral, injected, transdermal or implanted hormonal methods of contraception;&#xD;
                  placement of an intrauterine device (IUD) or intrauterine system (IUS); barrier&#xD;
                  methods of contraception: condom or occlusive cap (diaphragm or cervical/vault&#xD;
                  caps) with spermicidal foam/gel/film/cream/suppository.&#xD;
&#xD;
          -  Capable of inhaling dry powder.&#xD;
&#xD;
          -  Willing to sign informed consent&#xD;
&#xD;
          -  Willing and able to follow the study procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of hypertonic saline more than 2 times a day. If hypertonic saline is used, OligoG&#xD;
             inhalation should be taken at least 15 minutes after completion of hypertonic saline&#xD;
             therapy.&#xD;
&#xD;
          -  Use of CFTR modulator therapies.&#xD;
&#xD;
          -  Clinically significant abnormal findings of haematology or clinical chemistry;&#xD;
&#xD;
               -  Elevated gamma GT (GGT), ALT, or AST &gt; 3x the upper normal limit of normal (ULN)&#xD;
&#xD;
               -  Bilirubin &gt;2x ULN&#xD;
&#xD;
               -  Abnormal renal function, with a creatinine clearance calculated &lt;50ml/min&#xD;
&#xD;
               -  Haemoglobin &lt;10g/dL&#xD;
&#xD;
          -  History of any comorbidity that, in the opinion of the investigator, might distort the&#xD;
             results of the study or cause an additional risk in administering study drug to the&#xD;
             patient.&#xD;
&#xD;
          -  Pulmonary exacerbation within 28 days prior to randomisation.&#xD;
&#xD;
          -  Change in CF therapy within 28 days before randomisation (first dose of IMP).&#xD;
&#xD;
          -  Pregnant or breastfeeding females.&#xD;
&#xD;
          -  History of allergic reactions to the ingredients of the IMP according to Common&#xD;
             Terminology Criteria for Adverse Events (CTCAE) grade 3 or 4, including lactose and&#xD;
             milk protein.&#xD;
&#xD;
          -  Patients unable to perform pulmonary function tests according to the ATS/ERS criteria.&#xD;
&#xD;
          -  Uncontrolled or unstable chronic diseases (e.g. congestive heart failure, cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations) that would limit the compliance&#xD;
             with study requirements in the opinion of the investigator.&#xD;
&#xD;
          -  Any acute illness in the last 14 days&#xD;
&#xD;
          -  History of, or planned organ transplantation.&#xD;
&#xD;
          -  Lung infection with organisms associated with a more rapid decline in pulmonary status&#xD;
             (including, but not limited to Burkholderia cenocepacia, Burkholderia dolosa, and&#xD;
             Mycobacterium abscessus). For subjects who have had a history of a positive culture,&#xD;
             the following criteria will be used to determine whether the subject is free of&#xD;
             infection with such organisms:-&#xD;
&#xD;
               -  The subject has not had a respiratory tract culture positive for these organisms&#xD;
                  within the 12 months before the date of informed consent, and&#xD;
&#xD;
               -  The subject has had at least 2 respiratory tract cultures negative for such&#xD;
                  organisms within the 12 months before the date of informed consent, with the&#xD;
                  first and last of these separated by at least 3 months, and the most recent one&#xD;
                  within the 6 months before the date of informed consent.&#xD;
&#xD;
          -  Active allergic bronchopulmonary aspergillosis (ABPA) in the last 12 months prior to&#xD;
             the Screening Visit, that has received pharmacological treatment for ABPA.&#xD;
&#xD;
          -  Requirement for continuous (24 hour/day) oxygen supplementation.&#xD;
&#xD;
          -  Patients currently receiving any other investigational treatment, or who have&#xD;
             participated in a clinical study within 4 weeks (28 days) prior to the screening&#xD;
             visit.&#xD;
&#xD;
          -  Current malignant disease (with the exception of basal cell carcinoma and cervical&#xD;
             neoplasia).&#xD;
&#xD;
          -  Any medical or psychological condition, other than CF, which in the opinion of the&#xD;
             investigator exposes the patient to an unacceptably high risk.&#xD;
&#xD;
          -  Patients with documented or suspected, clinically significant, alcohol or drug abuse&#xD;
             as per Investigator's discretion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Wark</last_name>
    <role>Principal Investigator</role>
    <affiliation>John Hunter Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>John Hunter Hospital</name>
      <address>
        <city>Newcastle</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>January 29, 2019</study_first_submitted>
  <study_first_submitted_qc>January 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2019</study_first_posted>
  <last_update_submitted>May 25, 2020</last_update_submitted>
  <last_update_submitted_qc>May 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cystic fibrosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03822455
org study id: ORDCF205
nct id: NCT03822455
lead sponsor: 
collaborator: 
has dmc: No
is fda regulated drug: No
is fda regulated device: No
A double-blind, randomised study of OligoG DPI compared to placebo DPI, both on top of
      standard-of-care, to assess safety, efficacy and tolerability. Adult patients with Cystic
      Fibrosis will be included in the study.
The alginate oligosaccharide OligoG CF-5/20 dry powder for inhalation (OligoG DPI) represents
      a novel therapeutic approach for patients with cystic fibrosis (CF). OligoG has been shown to
      release stagnant mucus, modulate sputum rheology and disrupt the biofilm formation often
      typically observed in CF. These properties will in turn facilitate mucus clearance and
      promote effectiveness of antibiotic therapy against the chronic pulmonary infections
      characteristic of CF.

      Patients with CF (age 18 years or older) will be eligible to participate in this study.

      The design will be a randomised, blinded, placebo-controlled pilot study for proof of concept
      that OligoG DPI can improve lung function in adult CF patients. Study medication will be
      given twice daily for twelve weeks on top of standard of care (SOC). Thirty-three patients
      will be included, out of which twenty-two shall receive OligoG, and eleven shall receive
      placebo.

      After all patients have completed the 12 week double blind treatment period, all patients
      will be offered open-label OligoG twice daily, in addition to standard of care, for 12
      months.

      The primary endpoint will be absolute change i percent predicted FEV1

      Exploratory parameters will include sputum microbiology.
allocation: Randomized
intervention model: Parallel Assignment
intervention model description: Randomised, double blind, placebo controlled
primary purpose: Treatment
masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
masking description: Patients will be randomised to receive OligoG or placebo DPI. The investigational medicinal products will have identical appearance
measure: FEV1 percent predicted
time frame: Baseline compared to 12 weeks
description: Absolute change in percent Forced Expiratory Volume in one second,
measure: Pulmonary exacerbation rate
time frame: 6 months before treatment, 6 months after treatment,
description: rate of pulmonary exacerbations
arm group label: OligoG DPI
arm group type: Active Comparator
description: Active DPI containing the oligosaccharide OligoG and excipients
arm group label: Placebo DPI
arm group type: Placebo Comparator
description: Placebo DPI containing lactose and excipients
intervention type: Drug
intervention name: OligoG DPI
description: OligoG Dry Powder for Inhalation
arm group label: OligoG DPI
arm group label: Placebo DPI
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
last name: Peter Wark
role: Principal Investigator
affiliation: John Hunter Hospital
facility: 
country: Australia
responsible party type: Sponsor
mesh term: Cystic Fibrosis
mesh term: Fibrosis
sharing ipd: No